Advertisement

Thyroid Malignancies

  • K. B. Ain
Chapter
  • 109 Downloads

Abstract

Most oncologists have little experience and training in evaluation and management of the most common differentiated thyroid cancers. This is because such malignancies have historically been the bailiwick of endocrinologists, who are versed in nuclear medicine, while traditional chemotherapy agents have not demonstrated any significant clinical activity. Effective clinical management requires an approach distinct from other oncologic diseases. In addition, the approach to differentiated papillary and follicular thyroid carcinomas is different from the approach to anaplastic carcinomas, medullary carcinomas, thyroid lymphomas, and a host of rare thyroid malignancies. The following synopsis provides an overview of clinical management methods for the range of thyroid malignancies.

Keywords

Thyroid Cancer Thyroid Carcinoma Thyroid Nodule Papillary Carcinoma Medullary Thyroid Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Landis SH, Murray T, Bolden S, Wingo PA (1998) Cancer statistics, 1998. Ca Cancer J Clin 48:6–29PubMedCrossRefGoogle Scholar
  2. 2.
    Harach HR, Franssila KO, Wasenius V-M (1985) Occult papillary carcinoma of the thyroid. Cancer 56:531–538PubMedCrossRefGoogle Scholar
  3. 3.
    Parkin DM, Stiller CA, Draper GJ, Bieber CA, Terracini B, Young JL (1988) International incidence of childhood cancer. International Agency for Research on Cancer, Lyon (IARC scientific publications, vol 87)Google Scholar
  4. 4.
    LiVolsi VA (1990) Surgical pathology of the thyroid. Saunders, PhiladelphiaGoogle Scholar
  5. 5.
    Tielens ET, Sherman SI, Hruban RH, Ladenson PW (1994) Follicular variant of papillary thyroid carcinoma. Cancer 73:424–431PubMedCrossRefGoogle Scholar
  6. 6.
    Gilliland FD, Hunt WC, Morris DM, Key CR (1997) Prognostic factors for thyroid carcinoma: a population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) Program 1973–1991. Cancer 79: 564–573PubMedCrossRefGoogle Scholar
  7. 7.
    Matsuzuka F, Miyauchi A, Katayama S, Narabayashi I, Ikeda H, Kuma K, Sugawara M (1993) Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases. Thyroid 3:93–99PubMedCrossRefGoogle Scholar
  8. 8.
    Lote K, Andersen K, Nordal E, Brennhovd 10 (1980) Familial occurrence of papillary thyroid carcinoma. Cancer 46: 1291–1297PubMedCrossRefGoogle Scholar
  9. 9.
    Ozaki O, Ito K, Kobayashi K, Suzuki A, Manabe Y, Hosoda Y (1988) Familial occurrence of differentiated, nonmedullary thyroid carcinoma. World J Surg 12:565–571PubMedCrossRefGoogle Scholar
  10. 10.
    Schneider AB (1990) Radiation-induced thyroid tumors. Endocrinol Metab Clin North Am 19:495–508PubMedGoogle Scholar
  11. 11.
    DeGroot LJ (1989) Diagnostic approach and management of patients exposed to irradiation to the thyroid. J Clin Endocrinol Metab 69:925–928PubMedCrossRefGoogle Scholar
  12. 12.
    Baverstock KF (1993) Thyroid cancer in children in Belarus after Chernobyl. World Health Stat Q 46:204–208PubMedGoogle Scholar
  13. 13.
    Demidchik EP, Kazakov VS, Astakhova LN, Okeanov AE, Demidchik YE (1994) Thyroid cancer in children after the Chernobyl accident: clinical and epidemiological evaluation of 251 cases in the Republic of Belarus. In: Nagataki S (ed) Nagasaki symposium on Chernobyl: update and future. Elsevier, Amsterdam, pp 21–30Google Scholar
  14. 14.
    Schneider AB, Ron E, Lubin J, Stovall M, Gierlowski TC (1993) Dose-response relationships for radiation-induced thyroid cancer and thyroid nodules: evidence for the prolonged effects of radiation on the thyroid. J Clin Endocrinol Metab 77:362–369PubMedCrossRefGoogle Scholar
  15. 15.
    National Cancer Institute (1997) Estimated exposures and thyroid doses received by the American people from iodine-131 in fallout following Nevada atmospheric nuclear bomb tests. National Cancer Institute, Bethesda MDGoogle Scholar
  16. 16.
    Franceschi S, Boyle P, Maisonneuve P, La Vecchia C, Burt AD, Kerr DJ, MacFarlane GJ (1993) The epidemiology of thyroid carcinoma. Crit Rev Oncog 4:25–52PubMedGoogle Scholar
  17. 17.
    Wohllk N, Cote GJ, Evans DB, Goepfert H, Ordonez NG, Gagel RF (1996) Application of genetic screening informate, Be the sdaMD of papillary thyroid carcinoma and multiple endocrine neoplasia type 2. Endocrinol Metab Clin North Am 25:1–25PubMedCrossRefGoogle Scholar
  18. 18.
    Bell B, Mazzaferri EL (1993) Familial adenomatous polyposis (Gardner’s syndrome) and thyroid carcinoma: a case report and review of the literature. Dig Dis Sci 38:185–190PubMedCrossRefGoogle Scholar
  19. 19.
    Ain KB (1995) Papillary thyroid carcinoma: etiology, assessment, and therapy. Endocrinol Metab Clin North Am 24:711–760PubMedGoogle Scholar
  20. 20.
    Thyresson HN, Doyle JA (1981) Cowden’s disease (multiple hamartoma syndrome). Mayo Clin Proc 56:179–184PubMedGoogle Scholar
  21. 21.
    Correa P, Chen VW (1995) Endocrine gland cancer. Cancer 75:338–352PubMedCrossRefGoogle Scholar
  22. 22.
    Cunningham MP, Duda RB, Recant W, Chmiel JS, Sylverter J, Fremgen A (1990) Survival discriminants for differentiated thyroid cancer. Am J Surg 160:344–347PubMedCrossRefGoogle Scholar
  23. 23.
    Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J (1985) Papillary carcinoma of the thyroid: a clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 55:805–828PubMedCrossRefGoogle Scholar
  24. 24.
    Shah JP, Loree TR, Dharker D, Strong EW, Begg C, Vlamis V (1992) Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 164:658–661PubMedCrossRefGoogle Scholar
  25. 25.
    Zimmerman D, Hay ID, Gough IR, Goellner JR, Ryan JJ, Grant CS, McConahey WM (1988) Papillary thyroid carcinoma in children and adults: long-term follow-up of 1039 patients conservatively treated at one institution during three decades. Surgery 104:1157–1166PubMedGoogle Scholar
  26. 26.
    Fassina AS, Montesco MC, Ninfo V, Denti P, Masarotto G (1993) Histological evaluation of thyroid carcinomas: reproducibility of the WHO classification. Tumori 79:314–320PubMedGoogle Scholar
  27. 27.
    Johnson TL, Lloyd RV, Thompson NW, Beierwaltes WH, Sisson JC (1988) Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol 12:22–27PubMedCrossRefGoogle Scholar
  28. 28.
    Ostrowski ML, Merino MJ (1996) Tall cell variant of papillary thyroid carcinoma: a reassessment and immunohistochemical study with comparison to the usual type of papillary carcinoma of the thyroid. Am J Surg Path 20:964–974PubMedCrossRefGoogle Scholar
  29. 29.
    Rüter A, Nishiyama R, Lennquist S (1997) Tall-cell variant of papillary thyroid cancer: disregarded entity? World J Surg 21:15–21PubMedCrossRefGoogle Scholar
  30. 30.
    Evans HL (1986) Columnar-cell carcinoma of the thyroid: a report of two cases of an aggressive variant of thyroid carcinoma. Am J Clin Pathol 85:77–80PubMedGoogle Scholar
  31. 31.
    Sobrinho-Simões M, Nesland JM, Johannessen JV (1988) Columnar-cell carcinoma. Another variant of poorly differentiated carcinoma of the thyroid. Am J Clin Pathol 89: 264–267PubMedGoogle Scholar
  32. 32.
    Wenig BM, Thompson LDR, Adair CF, Shmookler B, Heffess CS (1998) Thyroid papillary carcinoma of columnar cell type. Cancer 82:740–763PubMedCrossRefGoogle Scholar
  33. 33.
    Carcangiu ML, Bianchi S (1989) Diffuse sclerosing variant of papillary thyroid carcinoma: clinicopathologic study of 15 cases. Am J Surg Pathol 13:1041–1049PubMedCrossRefGoogle Scholar
  34. 34.
    Rosai J (1993) Papillary carcinoma. Monogr Pathol 35: 138–165PubMedGoogle Scholar
  35. 35.
    Soares J, Limbert E, Sobrinho-Simões (1989) Diffuse sclerosing variant of papillary thyroid carcinoma: a clinicopathologic study of 10 cases. Pathol Res Pract 185:200–206PubMedCrossRefGoogle Scholar
  36. 36.
    Sobrinho-Simões MA, Soares J, Carneiro F, Limbert E (1990) Diffuse follicular variant of papillary carcinoma of the thyroid: report of eight cases of a distinct aggressive type of thyroid tumor. Surg Pathol 3:189–203Google Scholar
  37. 37.
    Herrera MF, Hay ID, Wu PS-C, Goellner JR, Ryan JJ, Ebersold JR, Bergstralh EJ, Grant CS (1992) Hürthle cell (oxyphilic) papillary thyroid carcinoma: a variant with more aggressive biologic behavior. World J Surg 16: 669–675PubMedCrossRefGoogle Scholar
  38. 38.
    Sobrinho-Simões MA, Nesland JM, Holm R, Sambade MC, Johannessen JV (1985) Hürthle cell and mitochondrionrich papillary carcinomas of the thyroid gland: an ultrastructural and immunocytochemical study. Ultrastruct Pathol 8:131–142PubMedCrossRefGoogle Scholar
  39. 39.
    Franssila KO, Ackerman LV, Brown CL, Hedinger CE (1985) Session II: follicular carcinoma. Semin Diagn Pathol 2: 101–122PubMedGoogle Scholar
  40. 40.
    Grebe SKG, Hay ID (1995) Follicular thyroid cancer. Endocrinol Metab Clin North Am 24:761–801PubMedGoogle Scholar
  41. 41.
    Schürmann G, Mattfeldt T, Feichter G, Koretz K, Möller P, Buhr H (1991) Stereology, flow cytometry, and immunohistochemistry of follicular neoplasms of the thyroid gland. Hum Pathol 22:179–184PubMedCrossRefGoogle Scholar
  42. 42.
    Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418–428PubMedCrossRefGoogle Scholar
  43. 43.
    Robbins J, Merino MJ, Boice JD Jr, Ron E, Ain KB, Alexander HR, Norton JA, Reynolds J (1991) Thyroid cancer: a lethal neoplasm. Ann Intern Med 115:133–147PubMedGoogle Scholar
  44. 44.
    Carcangiu ML, Zampi G, Rosai J (1984) Poorly differentiated (“insular”) thyroid carcinoma: a reinterpretation of Langhans’ “wuchernde Struma”. Am J Surg Pathol 8: 655–668PubMedCrossRefGoogle Scholar
  45. 45.
    Hassoun AAK, Hay ID, Goellner JR, Zimmerman D (1997) Insular thyroid carcinoma in adolescents: a potentially lethal endocrine malignancy. Cancer 79:1044–1048PubMedCrossRefGoogle Scholar
  46. 46.
    Justin EP, Seabold JE, Robinson RA, Walker WP, Gurll NJ, Hawes DR (1991) Insular carcinoma: a distinct thyroid carcinoma with associated iodine-131 localization. J Nucl Med 32:1358–1363PubMedGoogle Scholar
  47. 47.
    Rosai J, Saxén EA, Woolner L (1985) Session III: undifferentiated and poorly differentiated carcinoma. Semin Diagn Pathol 2:123–136PubMedGoogle Scholar
  48. 48.
    Carcangiu ML, Steeper T, Zampi G, Rosai J (1985) Anaplastic thyroid carcinoma: a study of 70 cases. Am J Clin Pathol 83:135–158PubMedGoogle Scholar
  49. 49.
    Nusynowitz ML (1991) Differentiating anaplastic thyroid carcinomas. J Nucl Med 32:1363–1364PubMedGoogle Scholar
  50. 50.
    Aldinger KA, Samaan NA, Ibanez M, Hill CS Jr (1978) Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant cell carcinoma of the thyroid. Cancer 41:2267–2275PubMedCrossRefGoogle Scholar
  51. 51.
    Nishiyama RH, Dunn EL, Thompson NW (1972) Anaplastic spindle-cell and giant-cell tumors of the thyroid gland. Cancer 30:113–127PubMedCrossRefGoogle Scholar
  52. 52.
    Schröder S, Holl K, Padberg BC (1992) Pathology of sporadic and hereditary medullary thyroid carcinoma. Rec Res Cancer Res 125:19–45CrossRefGoogle Scholar
  53. 53.
    Cote GJ, Wohllk N, Evans D, Goepfert H, Gagel RF (1995) RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Baillieres Clin Endocrinol Metab 9:609–630PubMedCrossRefGoogle Scholar
  54. 54.
    Abdul-Rahman ZH, Gogas HJ, Tooze JA, Anderson B, Mansi J, Sacks NP, Finlayson CJ (1996) T-cell lymphoma in Hashimoto’s thyroiditis. Histopathol 29:455–459CrossRefGoogle Scholar
  55. 55.
    Weinstein LJ, Ain KB (1999) Primary thyroid lymphoma: a comprehensive assessment and clinical approach. Endocrinologist 9:45–51CrossRefGoogle Scholar
  56. 56.
    Anscombe AM, Wright DH (1985) Primary malignant lymphoma of the thyroid — a tumour of mucosa-associated lymphoid tissue: review of seventy-six cases. Histopathology 9:81–97PubMedCrossRefGoogle Scholar
  57. 57.
    Hedinger C (1981) Geographic pathology of thyroid diseases. Pathol Res Pract 171:285–292PubMedCrossRefGoogle Scholar
  58. 58.
    Mills SE, Gaffey MJ, Watts JC, Swanson PE, Wick MR, LiVolsi VA, Nappi O, Weiss LM (1994) Angiomatoid carcinoma and ‘angiosarcoma’ of the thyroid gland: a spectrum of endothelial differentiation. Am J Clin Pathol 102:322–330PubMedGoogle Scholar
  59. 59.
    Carcangiu ML, Zampi G, Rosai J (1985) Papillary thyroid carcinoma: a study of its many morphologic expressions and clinical correlates. Pathol Ann 20:1–44Google Scholar
  60. 60.
    DeGroot LJ, Kaplan EL, Shukla MS, Salti G, Straus FH (1995) Morbidity and mortality in follicular thyroid cancer. J Clin Endocrinol Metab 80:2946–2953PubMedCrossRefGoogle Scholar
  61. 61.
    Coburn MC, Wanebo HJ (1992) Prognostic factors and management considerations in patients with cervical metastases of thyroid cancer. Am J Surg 164:671–676PubMedCrossRefGoogle Scholar
  62. 62.
    Ozaki O, Ito K, Sugino K (1993) Clinico-pathologic study of pulmonary metastasis of differentiated thyroid carcinoma: age-, sex-, and histology-matched case-control study. Int Surg 78:218–220PubMedGoogle Scholar
  63. 63.
    McCaffrey TV, Bergstralh EJ, Hay ID (1994) Locally invasive papillary thyroid carcinoma: 1940–1990. Head Neck 16:165–172PubMedCrossRefGoogle Scholar
  64. 64.
    DeGroot LJ, Kaplan EL, Straus FH, Shukla MS (1994) Does the method of management of papillary thyroid carcinoma make a difference in outcome? World J Surg 18:123–130PubMedCrossRefGoogle Scholar
  65. 65.
    Loh K-C, Greenspan FS, Gee L, Miller TR, Yeo PPB (1997) Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 82:3553–3562PubMedCrossRefGoogle Scholar
  66. 66.
    Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ (eds) (1992) Manual for staging of cancer. American Joint Committee on Cancer. Lippincott, PhiladelphiaGoogle Scholar
  67. 67.
    Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK, O’Sullivan B (1997) A comparison of different staging systems’ predictability of patient outcome. Thyroid carcinoma as an example. Cancer 79:2414–2423PubMedCrossRefGoogle Scholar
  68. 68.
    Hermanek P, Sobin LH (1987) TNM classification of malignant tumours. Springer, Berlin Heidelberg New YorkCrossRefGoogle Scholar
  69. 69.
    Pacini F, Fugazzola L, Lippi F, Ceccarelli C, Centoni R, Miccoli P, Elisei R, Pinchera A (1992) Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. J Clin Endocrinol Metab 74:1401–1404PubMedCrossRefGoogle Scholar
  70. 70.
    Ashcraft MW, Van Herle AJ (1981) Management of thyroid nodules. II. Scanning techniques, thyroid suppressive therapy, and fine needle aspiration. Head Neck Surg 3:297–322PubMedCrossRefGoogle Scholar
  71. 71.
    Scheumann GFW, Gimm O, Wegener G, Hundeshagen H, Dralle H (1994) Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 18:559–567PubMedCrossRefGoogle Scholar
  72. 72.
    Dralle H, Damm I, Scheumann GF, Kotzerke J, Kupsch E, Geerlings H, Pichlmayr R (1994) Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 24:112–121PubMedCrossRefGoogle Scholar
  73. 73.
    Venkataraman GM, Yatin M, Ain KB (1998) Cloning of the human sodium-iodide symporter promoter and characterization in a differentiated human thyroid cell line, KAT-50. Thyroid 8:63–69PubMedCrossRefGoogle Scholar
  74. 74.
    Mazzaferri EL, Kloos RT (2000) Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions. Thyroid 10: 767–778PubMedCrossRefGoogle Scholar
  75. 75.
    Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, Ross DS, Deraska DJ, Davies TF, Valentine M, DeGroot LJ, Curran P, McEllin K, Reynolds J, Robbins J, Weintraub BD (1994) Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 78:188–196PubMedCrossRefGoogle Scholar
  76. 76.
    Ain KB, DeWitt PA, Gardner TG, Berryman SW (1994) Low-iodine tube-feeding diet for iodine-131 scanning and therapy. Clin Nucl Med 19:504–507PubMedCrossRefGoogle Scholar
  77. 77.
    Lakshmanan M, Schaffer A, Robbins J, Reynolds J, Norton J (1988) A simplified low iodine diet in I-131 scanning and therapy of thyroid cancer. Clin Nucl Med 13:866–868PubMedCrossRefGoogle Scholar
  78. 78.
    Goldman JM, Line BR, Aamodt RL, Robbins J (1980) Influence of triiodothyronine withdrawal time on 131I uptake postthyroidectomy for thyroid cancer. J Clin Endocrinol Metab 50:734–739PubMedCrossRefGoogle Scholar
  79. 79.
    Park H-M, Perkins OW, Edmondson JW, Schnute RB, Manatunga A (1994) Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 4:49–54PubMedCrossRefGoogle Scholar
  80. 80.
    Ain KB (1997) Management of thyroid cancer. In: Braverman LE (ed) Diseases of the thyroid. Humana Press, Totowa NJ,pp 287–317Google Scholar
  81. 81.
    Hoefnagel CA, Delprat CC, Marcuse HR, de Vijlder JJM (1986) Role of thallium-201 total-body scintigraphy in follow-up of thyroid carcinoma. J Nucl Med 27:1854–1857PubMedGoogle Scholar
  82. 82.
    Yen T-C, Lin H-D, Lee C-H, Chang SL, Yeh SH (1994) The role of technetium-99 m sestamibi whole-body scans in diagnosing metastatic Hürthle cell carcinoma of the thyroid gland after total thyroidectomy: a comparison with iodine-131 and thallium-201 whole-body scans. Eur J Nucl Med 21:980–983PubMedCrossRefGoogle Scholar
  83. 83.
    Scott GC, Meier DA, Dickinson CZ (1995) Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fiuorine-18-FDG, technetium-99m-pertechnetate and iodine-131-sodium iodide. J Nucl Med 36:1843–1845PubMedGoogle Scholar
  84. 84.
    Pineda JD, Lee T, Ain KB, Reynolds JC, Robbins J (1995) Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 80:1488–1492PubMedCrossRefGoogle Scholar
  85. 85.
    Demeure MJ, Clark OH (1990) Surgery in the treatment of thyroid cancer. Endocrinol Metab Clin North Am 19: 663–683PubMedGoogle Scholar
  86. 86.
    Soh EY, Clark OH (1996) Surgical considerations and approach to thyroid cancer. Endocrinol Metab Clin North Am 25:115–139PubMedCrossRefGoogle Scholar
  87. 87.
    Samuel AM, Sharma SM (1991) Differentiated thyroid carcinomas in children and adolescents. Cancer 67:2186–2190PubMedCrossRefGoogle Scholar
  88. 88.
    Wong JB, Kaplan MM, Meyer KB, Pauker SG (1990) Ablative radioactive iodine therapy for apparently localized thyroid carcinoma: a decision analytic perspective. Endocrinol Metab Clin North Am 19:741–760PubMedGoogle Scholar
  89. 89.
    Benua RS, Leeper RD (1986) A method and rationale for treating metastatic thyroid carcinoma with the largest safe dose of 131I. In: Medeiros-Neto G, Gaitan E (eds) Frontiers in thyroidology. Plenum Medical Book, New York, pp 1317–1321Google Scholar
  90. 90.
    Koong SS, Reynolds JC, Movius EG, Keenan AM, Ain KB, Lakshmanan MC, Robbins JR (1999) Lithium as a potential adjuvant to 131I therapy of metastatic, well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 84:912–916PubMedCrossRefGoogle Scholar
  91. 91.
    Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen I-W, Sperling MI, Saenger EL (1983) Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 309:937–941PubMedCrossRefGoogle Scholar
  92. 92.
    Phlips P, Hanzen C, Andry G, Van Houtte P, Früuling J (1993) Postoperative irradiation for thyroid cancer. Eur J Surg Oncol 19:399–404PubMedGoogle Scholar
  93. 93.
    Levendag PC, De Porre PMZR, van Putten WLJ (1993) Anaplastic carcinoma of the thyroid gland treated by radiation therapy. Int J Radiat Oncol Biol Phys 26:125–128PubMedCrossRefGoogle Scholar
  94. 94.
    Kim JH, Leeper RD (1987) Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 60:2372–2375PubMedCrossRefGoogle Scholar
  95. 95.
    Tennvall J, Lundell G, Hallquist A, Wahlberg P, Wallin G, Tibblin S (1994) Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Cancer 74:1348–1354PubMedCrossRefGoogle Scholar
  96. 96.
    Wong CS, Van Dyk J, Simpson WJ (1991) Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 20:3–9PubMedCrossRefGoogle Scholar
  97. 97.
    Ahuja S, Ernst H (1987) Chemotherapy of thyroid carcinoma. J Endocrinol Invest 10:303–310PubMedGoogle Scholar
  98. 98.
    Droz J-P, Schlumberger M, Rougier P, Ghosn M, Gardet P, Parmentier C (1990) Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 76:480–483PubMedGoogle Scholar
  99. 99.
    Asakawa H, Kobayashi T, Komoike Y, Maruyama H, Nakano Y, Tamaki Y, Matsuzawa Y, Monden M (1997) Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma. Anticancer Res 17:2757–2762PubMedGoogle Scholar
  100. 100.
    Ain KB, Tofiq S, Taylor KD (1996) Antineoplastic activity of Taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab 81: 3650–3653PubMedCrossRefGoogle Scholar
  101. 101.
    Ain KB, Egorin MJ, DeSimone PA (2000) Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10:587–594PubMedCrossRefGoogle Scholar
  102. 102.
    Orlandi F, Caraci P, Berruti A, Puligheddu B, Pivano G, Dogliotti L, Angeli A (1994) Chemotherapy with dacarbazine and 5-fiuorouracil in advanced medullary thyroid cancer. Ann Oncol 5:763–765PubMedGoogle Scholar
  103. 103.
    Ain KB, Pucino F, Shiver TM, Banks SM (1993) Thyroid hormone levels affected by time of blood sampling in thyroxine-treated patients. Thyroid 3:81–85PubMedCrossRefGoogle Scholar
  104. 104.
    Mazzaferri EL, Young RL (1981) Papillary thyroid carcinoma: a 10-year follow-up report of the impact of therapy in 576 patients. Am J Med 70:511–518PubMedCrossRefGoogle Scholar
  105. 105.
    Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB (1988) Papillary and follicular thyroid cancer: impact of treatment in 1,578 patients. Int J Radiat Oncol Biol Phys 14:1063–1075PubMedCrossRefGoogle Scholar
  106. 106.
    Fazio S, Biondi B, Carella C, Sabatini D, Cittadini A, Panza N, Lombardi G, Saccà L (1995) Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of β-blockade. J Clin Endocrinol Metab 80:2222–2226PubMedCrossRefGoogle Scholar
  107. 107.
    Marcocci C, Golia F, Bruno-Bossio G, Vignali E, Pinchera A (1994) Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab 78:818–823PubMedCrossRefGoogle Scholar
  108. 108.
    Schlesinger T, Flower MA, McCready VR (1989) Radiation dose assessments in radioiodine (131I) therapy. 1. The necessity for in vivo quantitation and dosimetry in the treatment of carcinoma of the thyroid. Radiother Oncol 14: 35–41PubMedCrossRefGoogle Scholar
  109. 109.
    Jhiang SM, Cho J-Y, Ryu K-Y, De Young BR, Smanik PA, McGaughy VR, Fischer AH, Mazzaferri EL (1998) An immunohistochemical study of Na+/I-symporter in human thyroid tissues and salivary gland tissues. Endocrinology 139:4416–4419PubMedCrossRefGoogle Scholar
  110. 110.
    Kaminsky SM, Levy O, Salvador C, Dai G, Carrasco N (1994) Na+-I-symport activity is present in membrane vesicles from thyrotopin-deprived non-I-transporting cultured thyroid cells. Proc Natl Acad Sci USA 91: 3789–3793PubMedCrossRefGoogle Scholar
  111. 111.
    Shimura H, Haraguchi K, Miyazaki A, Endo T, Onaya T (1997) Iodide uptake and experimental 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I-symporter gene. Endocrinology 138:4493–4496PubMedCrossRefGoogle Scholar
  112. 112.
    Spate VL, Morris JS, Nichols TA, Baskett CK, Mason MM, Horsman TL, Horn-Ross PL, Schiau AC, McDougall IR (1998) Longitudinal study of iodine in toenails following IV administration of an iodine-containing contrast agent. J Radioanalyt Nucl Chem 236:71–76CrossRefGoogle Scholar
  113. 113.
    Ain KB (1998) Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 8:715–726PubMedCrossRefGoogle Scholar
  114. 114.
    Ain KB (1999) Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol 16:64PubMedCrossRefGoogle Scholar
  115. 115.
    Venkataraman GM, Yatin M, Marcinek R, Ain KB (1999) Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. J Clin Endocrinol Metab 84: 2449–2457PubMedCrossRefGoogle Scholar
  116. 116.
    Blagosklonny MV, Giannakakou P, Wojtowicz M, Romanova LY, Ain KB, Bates SE, Fojo T (1998) Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 83:2516–2522PubMedCrossRefGoogle Scholar
  117. 117.
    Narimatsu M, Nagayama Y, Akino K, Yasuda M, Yamamoto T, Yang TT, Ohtsuru A, Namba H, Yamashita S, Ayabe H, Niwa M (1998) Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line. J Clin Endocrinol Metab 83:3668–3672PubMedCrossRefGoogle Scholar
  118. 118.
    Watanabe T, Sullenger BA (2000) Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. Proc Natl Acad Sci U S A 97: 8490–8494PubMedCrossRefGoogle Scholar
  119. 119.
    Nagayama Y, Nishihara E, Iitaka M, Namba H, Yamashita S, Niwa M (1999) Enhanced efficacy of transcriptionally targeted suicide gene/prodrug therapy for thyroid carcinoma with the Cre-loxP system. Cancer Res 59:3049–3052PubMedGoogle Scholar
  120. 120.
    Satake S, Sugawara I, Watanabe M, Takami H (1997) Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines. Cancer Letters 116:33–39PubMedCrossRefGoogle Scholar
  121. 121.
    Hermanek P, Henson DE, Hutter RVP, Sobin LH (1993) TNM supplement 1993: a commentary on uniform use. International Union Against Cancer. Springer, Berlin Heidelberg New YorkGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • K. B. Ain

There are no affiliations available

Personalised recommendations